Figure 4 — Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide

Research Papers|Volume 13, Issue 0|pp. 120–129

Selective blood–brain barrier penetration and tumor targeting of nitrosylcobalamin in glioblastoma: Pharmacokinetics, tissue distribution, and synergistic activity with trail and temozolomide

Back to articleFigure 4(4 of 4)

100%

Figure 4.Synergistic inhibition of glioblastoma cell proliferation by NO-Cbl in combination with TRAIL or TMZ(A) Growth of U87 treated with TRAIL, NO-Cbl or their combination and (B) D54 cells treated with TMZ, NO-Cbl, or their combination at three dose levels for each treatment. Statistical significance was determined using two-tailed Student’s t-tests between treatment groups (TRAIL vs. NO-Cbl, TRAIL vs. Combo, and NO-Cbl vs. Combo for U87; TMZ vs. NO-Cbl, TMZ vs. Combo, and NO-Cbl vs. Combo for D54). Significance levels are denoted as: p < 0.05 (^*), p < 0.01 (^**), p < 0.001 (^***). Combination index plotted against fraction affected for U87 (C) and D54 (D), treated with TRAIL + NO-Cbl at corresponding combination doses. Combination index values of <1 indicate synergism.